Novartis Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Phase 3 trial results of baricitinib in juvenile idiopathic arthritis (JIA) show the JAK inhibitor increases time to flare and reduces frequency of flares.